Zoetis Inc. (ZTS) Receives Average Recommendation of “Buy” from Analysts
Shares of Zoetis Inc. (NYSE:ZTS) have received a consensus recommendation of “Buy” from the fifteen analysts that are covering the firm. Three research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, eight have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $55.71.
A number of brokerages recently commented on ZTS. Bank of America Corp. began coverage on Zoetis in a report on Thursday, September 29th. They set a “buy” rating and a $60.00 target price for the company. Citigroup Inc. raised their target price on Zoetis from $50.00 to $53.00 and gave the company a “neutral” rating in a report on Thursday, August 4th. Credit Suisse Group AG restated an “outperform” rating and set a $60.00 target price on shares of Zoetis in a report on Tuesday, August 23rd. Argus raised their target price on Zoetis from $54.00 to $58.00 and gave the company a “below average” rating in a report on Friday, September 9th. Finally, Barclays PLC raised their target price on Zoetis from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Thursday, August 4th.
Zoetis (NYSE:ZTS) opened at 50.18 on Wednesday. The firm has a market cap of $24.84 billion, a P/E ratio of 39.08 and a beta of 1.01. Zoetis has a 12-month low of $38.26 and a 12-month high of $53.14. The stock’s 50 day moving average is $51.25 and its 200 day moving average is $49.01.
Zoetis (NYSE:ZTS) last announced its earnings results on Wednesday, August 3rd. The company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. Zoetis had a return on equity of 77.58% and a net margin of 13.15%. The company earned $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the business posted $0.43 EPS. Zoetis’s revenue for the quarter was up 2.8% on a year-over-year basis. On average, equities research analysts expect that Zoetis will post $1.91 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Thursday, November 3rd will be given a dividend of $0.095 per share. This represents a $0.38 annualized dividend and a yield of 0.76%. The ex-dividend date of this dividend is Tuesday, November 1st. Zoetis’s dividend payout ratio (DPR) is 29.69%.
In other news, insider Heidi C. Chen sold 32,097 shares of the business’s stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $50.98, for a total value of $1,636,305.06. Following the transaction, the insider now owns 46,060 shares of the company’s stock, valued at $2,348,138.80. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michael B. Mccallister bought 2,000 shares of the company’s stock in a transaction dated Tuesday, September 6th. The stock was bought at an average cost of $51.34 per share, for a total transaction of $102,680.00. The disclosure for this purchase can be found here. Company insiders own 0.05% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. raised its position in Zoetis by 21.8% in the first quarter. UBS Asset Management Americas Inc. now owns 1,390,919 shares of the company’s stock worth $61,660,000 after buying an additional 249,196 shares during the last quarter. Lazard Asset Management LLC raised its position in Zoetis by 2.7% in the first quarter. Lazard Asset Management LLC now owns 18,464,624 shares of the company’s stock worth $818,534,000 after buying an additional 478,750 shares during the last quarter. BB&T Securities LLC raised its position in Zoetis by 112.2% in the first quarter. BB&T Securities LLC now owns 23,145 shares of the company’s stock worth $1,026,000 after buying an additional 12,237 shares during the last quarter. Aviva PLC raised its position in Zoetis by 1.5% in the first quarter. Aviva PLC now owns 254,623 shares of the company’s stock worth $11,287,000 after buying an additional 3,738 shares during the last quarter. Finally, Ancora Inverness LLC raised its position in Zoetis by 21.8% in the first quarter. Ancora Inverness LLC now owns 47,126 shares of the company’s stock worth $2,089,000 after buying an additional 8,441 shares during the last quarter. 93.12% of the stock is currently owned by institutional investors and hedge funds.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.